Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Releases New Data from Failed Phase IIb Study of RSV Drug

Premium

Alnylam Pharmaceuticals this week released the complete results from a phase IIb study of its respiratory syncytial virus drug ALN-RSV01, roughly three months after the company confirmed that the trial failed to meet its primary endpoint.

The company said that it still plans to meet with US and European regulators about the data, and that it aims to make a final decision by year end on whether development of the drug will continue.

In the phase IIb study, 87 lung-transplant patients were randomized in a one-to-one drug-to-placebo ratio, with 45 patients receiving ALN-RSV01 and 42 receiving placebo, defining the overall intent-to-treat study cohort. In May, Alnylam said that the trial did not meet its primary endpoint of reduced incidence of new or progressive bronchiolitis obliterans syndrome, or BOS, a non-reversible obstructive lung disease, at 180 days (GSN 5/31/2012).

However, ALN-RSV01 treatment was associated with “a statistically significant reduction in the incidence of day 180” BOS in certain subsets of enrolled patients.

Newly released study findings, which were presented this month at the European Respiratory Society's annual congress in Vienna, show that ALN-RSV01 treatment triggered a statistically significant reduction in day 90 BOS as compared with placebo as measured in the overall intent-to-treat study cohort with an overall effect size of 52, according to Alnylam.

“Further, ALN-RSV01 showed an enhanced treatment effect size of 88 percent toward day 180 BOS in patients treated within five days from symptom onset,” the company said. “In aggregate, the newly presented results support the conclusion that treatment of RSV-infected lung transplant patients with ALN-RSV01 is generally safe and well tolerated and associated with a decreased incidence of new or progressive BOS.”

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.